Navigation Links
Defending against chemical acts of terrorism
Date:4/20/2012

ions into the gene encoding a target enzyme, in this case PON1. The mutated versions of the gene are then put back into bacteria, which produce the enzymes for testing. The goal was to end up with enzymes capable of detoxifying G-type nerve agents before those nerve agents could reach their target and cause harm. Those that passed the initial test went on to further rounds of evolution and testing.

After four rounds of evolution, the researchers obtained PON1 variants that worked up to 340 times better than those produced previously. Overall, the researches reported that the PON1 variants showed 40- to 3,400-fold higher efficiency than the normal enzyme in metabolizing the three most toxic G-type nerve agents.

These new and improved PON1 enzymes have become promising candidates for use as preventive and postexposure treatments in the event of a terrorist attack.

"We hope that our enzymes would be able to act together with currently available drugs to improve survival rates following intoxication," Goldsmith said. More broadly, the findings show the power of laboratory evolution to completely reshape existing enzymes for a variety of uses.


'/>"/>

Contact: Elisabeth (Lisa) Lyons
elyons@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Page: 1 2

Related biology technology :

1. 3M Withdraws Blackmail Claims Against Harvey Boulter From New York Court
2. Nanosurgery and the fight against cancer: Major breakthrough at Polytechnique Montral
3. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
4. MU researchers identify key plant immune response in fight against bacteria
5. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
6. Stemline Therapeutics, Inc. Announces Two Poster Presentations of SL-401 Efficacy Data Against Lymphoid Cancers at the 53rd Annual Meeting of the American Society of Hematology (ASH)
7. Taksta™ (fusidic acid) Demonstrates Activity Against MRSA Isolated From Cystic Fibrosis Patients
8. SomaGenics sshRNA Technology Demonstrates Efficacy of RNAi Against Hepatitis C Virus
9. Kelly Price Joins Los Angeles County Affiliate of Susan G. Komen for the Cure in the Fight Against Breast Cancer
10. World Hepatitis Alliance Warns that Stigma is a Major Threat to New Initiative Against Hepatitis Epidemic
11. Trudeau Institute announces a discovery in the fight against sepsis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... -- Quest Diagnostics Incorporated (NYSE: DGX ), the world,s ... is scheduled to speak at the Jefferies 2015 Global ... the company,s President and CEO, will discuss the company,s ... scheduled for Tuesday, June 2, 2015 at 8:00 a.m. ... live during the conference and will be available to ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) has ... "Neuroprotection - Drugs, Markets and Companies" ... the role of neuroprotection in acute disorders such ... as well as in chronic diseases such as ... of damage to neural tissues are similar in ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 BioNorth ... serving and representing the life sciences industry in ... of Directors meeting at The Foundry in Dallas ... the organization brought together a broad spectrum of ... underscored the organization's early successes in partnering with ...
(Date:5/28/2015)... and London (PRWEB) May 28, 2015 ... of Computer Aided Engineering software, announced today it ... Inc. (PSRI). CD-adapco will provide state-of-the-art engineering simulation ... will share their expertise and experiences in analyzing ... refining industry members and advance the understanding of ...
Breaking Biology Technology:Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
... Foundation announced an agreement to underwrite a joint effort ... to search for personalized cancer therapies through biomarker research. ... will provide 2.5 million euros over the next five ... VHIO.  MGH has also committed to match up to ...
... Nov. 16, 2011 Fate ... Patent and Trademark Office has granted a patent covering ...  U.S. Patent No. 8,044,201 entitled "Stem Cell Cultures" claims ... well as compositions and cell culture media comprising Thiazovivin. ...
... scientists have developed a method for stacking synthetic DNA ... that may lead to more accurate measurements for research ... employ metal electrodes coated with enzymes that react with ... measured. But the inefficiency of those sensors leads to ...
Cached Biology Technology:BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelona's Vall d'Hebron Hospital in Biomarker Research for Personalized Cancer Therapies 2Fate Therapeutics Strengthens Its iPSC Platform 2Fate Therapeutics Strengthens Its iPSC Platform 3New biosensor benefits from melding of carbon nanotubes, DNA 2
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/18/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... 20 May 2012. The Stem Cells and Cancer Research ... Vall d,Hebrn Institute of Oncology (VHIO) has identified the ... used in clinical trials for colon cancer treatment. The ... with Professor Alberto Muozs laboratory at the Instituto de ...
... PHOENIX, May 18, 2012 /PRNewswire-iReach/ -- With ... out of sight, and research to find "cures" continuing ... remain "a few years away," a small but growing ... human consciousness. A number of healing practices that rely ...
... did not set out to discover one of the longest ... and a team of researchers all current or former ... published in Scientific Reports . Their findings shed ... lead to widespread, yet largely invisible, disruptions of ecological interaction ...
Cached Biology News:Discovery of mechanisms predicting response to new treatments in colon cancer 2Discovery of mechanisms predicting response to new treatments in colon cancer 3Healing Method from Australia Addresses the Human Genome 2Stanford scientists document fragile land-sea ecological chain 2
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
... an internal standard for the quantification of ... 5-OxoETE is a polyunsaturated keto acid formed ... neutrophils. It stimulates cytosolic calcium levels in ... 5-OxoETE selectively stimulates the migration and degranulation ...
...
... The dsRNA Marker consists of ten double-stranded ... 300, 400, 500 and 1,000 base pairs. ... marker for determinating sizes of double-stranded RNAs. ... the dsRNA Marker is adjusted to approximately ...
Biology Products: